Subscriptions are live: We're on the subscription model now, early-access price $24.99/month, with day, week, and longer plans too. New accounts start with 5 free premium days. Prefer to donate? Donations grant premium time and are logged on your profile page.

$AVBP

ArriVent BioPharma, Inc. Common Stock

XNAS

$33.66+0.00%+$0.0000Prev $33.66LIVE Full chart Live alerts
No recent price bars, the chart lights up when AVBP starts printing.

As of the latest tick, AVBP is trading at $33.66, up 0.00% versus the previous close of $33.66.

Key Stats

Price
$33.66
Change today
+0.00%
Previous close
$33.66
52-week range
$16.10 – $35.83
Avg daily volume
436K
Exchange
XNAS

$AVBP Sentiment

Bullish
Bearish78Bullish
📰 News: 6 bull · 0 bearToday: +0.0%👥 Community: 0 bull · 0 bear

Blend of news sentiment, today’s move, and community votes. Not investment advice.

$AVBP Activity

News, unusual-volume alerts, AI-trader trades and community chatter — the whole story, newest first.

Alert· 2d ago +0.3% vs EMA
AVBP 200EMA (1m) Trending · 91 bars · L3 · +0.33% above EMA · slope +0.10%
at $33.66
Alert· 2d ago 39.2× RVOL
AVBP hit 39.187x RVOL at 1:53 PM ET
at $33.82
Alert· 2d ago +1.3% vs EMA
$AVBP near 200 EMA: +1.34% from 200 EMA at 1:34 PM ET
at $33.85
Alert· 2d ago -1.06%
$AVBP moved -1.06% in 1 min (Level 1) at 1:34 PM ET
at $33.85
Alert· 2d ago 9.0× RVOL
AVBP hit 8.987x RVOL at 1:15 PM ET
at $33.42
Alert· 2d ago -0.1% vs EMA
$AVBP near 200 EMA: -0.10% from 200 EMA at 11:24 AM ET
at $33.37
Alert· 2d ago -1.32%
$AVBP moved -1.32% in 1 min (Level 1) at 11:24 AM ET
at $33.41
Alert· 2d ago 3.7× RVOL
AVBP hit 3.721x RVOL at 11:24 AM ET
at $33.37
Alert· 2d ago 2.9× RVOL
AVBP hit 2.903x RVOL at 10:50 AM ET
at $33.16
Alert· 4d ago 29.1× RVOL
AVBP hit 29.080x RVOL at 12:11 PM ET
at $33.00
News· GlobeNewswire Inc.· 66d ago Bullish
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
News· GlobeNewswire Inc.· 117d ago Bullish
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
News· Benzinga· 157d ago Bullish
$207B Market Shift: The Race for Fast Track Approval in Oncology
News· Benzinga· 181d ago Bullish
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
News· GlobeNewswire Inc.· 202d ago Bullish
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
News· Benzinga· 208d ago Bullish
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
News· The Motley Fool· 335d ago Neutral
ArriVent Posts Wider Loss in Fiscal Q2
News· GlobeNewswire Inc.· 376d ago Neutral
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
Free alerts

Get free $AVBP alerts the moment volume spikes

Our scanner flagged $AVBP 10 times in the last 30 days. Create a free account to track $AVBP, build a watchlist, and get instant unusual-volume alerts — plus 5 free premium days, no card needed.

Real-time RVOL & momentum alerts Personal watchlist & price alerts
Sign up free with email

No card · 5 premium days · join 800+ traders

AVBP stock FAQ

What is the AVBP stock price today?

AVBP last traded at $33.66, up 0.00% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).

Where can I see live AVBP alerts?

The AVBP Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged AVBP 10 times in the last 30 days.

What exchange is AVBP on?

AVBP (ArriVent BioPharma, Inc. Common Stock) trades on XNAS.

Is AVBP good for day trading?

That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge AVBP for yourself. This is not investment advice.

Live data from TheDesperateTrader scanner. Not investment advice.